Kailera Therapeutics names Nur Nicholson chief technology officer
KLRA•Kailera appoints new chief technology officer
- Kailera Therapeutics named Nur Nicholson chief technology officer, effective Aug. 31, 2026.
- The role centers on scaling manufacturing and supply capabilities as ribupatide injection moves through global Phase 3 trials.
- The Phase 3 program for ribupatide oral is slated to start in the first half of next year.
- Nicholson was chief technical operations officer at Apellis Pharmaceuticals, leading technical operations through its shift to commercial scale.
- Earlier roles included global supply chain leadership at Galderma, plus operations posts at Alcon Pharmaceuticals, a Novartis company.
Related News
Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
AURA•
Zura Bio posts corporate overview highlighting tibulizumab dual IL-17/BAFF bispecific program in Phase 2 development
ZURA•
